Vertex Pharmaceuticals Incorporated is set to present updated data from the Phase 1/2 portion of the FORWARD-101 clinical trial of zimislecel at the American Diabetes Association $(ADA.AU)$ annual conference in Chicago. The presentation, part of the symposium "Innovation and Progress in Stem Cell-Derived Islet-Cell Replacement Therapy," will take place on June 20, 2025. The data, simultaneously published in the New England Journal of Medicine, highlights the potential of zimislecel for treating type 1 diabetes.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.